Literature DB >> 15358012

Cardiovascular therapies and risk for development of diabetes.

Carl J Pepine1, Rhonda M Cooper-Dehoff.   

Abstract

The prevalence of diabetes is increasing, and patients with diabetes are at increased risk of adverse cardiovascular outcomes. Recently, the results from 11 large randomized clinical trials have suggested a difference in the emergence of new diabetes according to cardiovascular medication use. Treatment with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and calcium antagonists yielded a lower incidence of diabetes development than beta-blockers and diuretics. Physicians should consider this possible diabetes consequence when prescribing long-term beta-blockers and diuretics, particularly in patients at high risk of developing diabetes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15358012     DOI: 10.1016/j.jacc.2004.03.071

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

Review 1.  Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension.

Authors:  Neil A Reynolds; Antona J Wagstaff; Susan J Keam
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Prediabetes and cardiovascular risk in hypertensive patients.

Authors:  Julian Segura; Cecilia Roldán; Jose A García-Donaire; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2006-05       Impact factor: 5.369

Review 3.  Lipid effects of antihypertensive medications.

Authors:  Roderick Deano; Matthew Sorrentino
Journal:  Curr Atheroscler Rep       Date:  2012-02       Impact factor: 5.113

4.  Angiotensin II type I receptor gene polymorphism: anthropometric and metabolic syndrome traits.

Authors:  M R Abdollahi; T R Gaunt; H E Syddall; C Cooper; D I W Phillips; S Ye; I N M Day
Journal:  J Med Genet       Date:  2005-05       Impact factor: 6.318

Review 5.  Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum.

Authors:  Rhonda M Cooper-DeHoff; Michael A Pacanowski; Carl J Pepine
Journal:  J Am Coll Cardiol       Date:  2009-02-03       Impact factor: 24.094

6.  Thiazide-induced dysglycemia: it's time to take notice.

Authors:  Rhonda M Cooper-DeHoff
Journal:  Expert Rev Cardiovasc Ther       Date:  2008-11

Review 7.  Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects.

Authors:  Jason H Karnes; Rhonda M Cooper-DeHoff
Journal:  Expert Rev Cardiovasc Ther       Date:  2009-06

Review 8.  Metabolic syndrome and cardiovascular disease: challenges and opportunities.

Authors:  Rhonda M Cooper-DeHoff; Carl J Pepine
Journal:  Clin Cardiol       Date:  2007-12       Impact factor: 2.882

9.  Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension?

Authors:  Panteleimon A Sarafidis; George L Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-05       Impact factor: 3.738

10.  Effects of ACE inhibitors on insulin resistance and lipid profile in children with metabolic syndrome.

Authors:  Eda Celebi Bitkin; Mehmet Boyraz; Necati Taşkın; Arzu Akçay; Korkut Ulucan; Mehmet Bedir Akyol; Teoman Akçay
Journal:  J Clin Res Pediatr Endocrinol       Date:  2013-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.